These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25829215)

  • 1. The monitoring medicines project: a multinational pharmacovigilance and public health project.
    Pal SN; Olsson S; Brown EG
    Drug Saf; 2015 Apr; 38(4):319-28. PubMed ID: 25829215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiatives to identify and mitigate medication errors in England.
    Cousins D; Gerrett D; Richards N; Jadeja MM
    Drug Saf; 2015 Apr; 38(4):349-57. PubMed ID: 25735854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.
    Härmark L; van Hunsel F; Grundmark B
    Drug Saf; 2015 Apr; 38(4):337-47. PubMed ID: 25627832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study.
    Pozsgai K; Szűcs G; Kőnig-Péter A; Balázs O; Vajda P; Botz L; Vida RG
    Front Pharmacol; 2022; 13():964399. PubMed ID: 36147337
    [No Abstract]   [Full Text] [Related]  

  • 7. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
    Matos C; van Hunsel F; Joaquim J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance of Biologics in a Multisource Environment.
    Sagi S; Cohen HP; Woollett GR
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1249-1254. PubMed ID: 29172979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacovigilance in India: Present Scenario and Future Challenges.
    Kalaiselvan V; Srivastava S; Singh A; Gupta SK
    Drug Saf; 2019 Mar; 42(3):339-346. PubMed ID: 30269244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports.
    Leitzen S; Dubrall D; Toni I; Stingl J; Christ P; Köberle U; Schmid M; Neubert A; Sachs B
    Paediatr Drugs; 2023 Mar; 25(2):203-215. PubMed ID: 36369590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems.
    Pal SN; Duncombe C; Falzon D; Olsson S
    Drug Saf; 2013 Feb; 36(2):75-81. PubMed ID: 23329541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance in Europe and North America: divergent approaches.
    Wiktorowicz M; Lexchin J; Moscou K
    Soc Sci Med; 2012 Jul; 75(1):165-70. PubMed ID: 22521677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing a national combined reporting form for adverse drug reactions and medication errors.
    Tanti A; Serracino-Inglott A; Borg JJ
    East Mediterr Health J; 2015 Jun; 21(4):246-55. PubMed ID: 26077519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific features of medicines safety and pharmacovigilance in Africa.
    Isah AO; Pal SN; Olsson S; Dodoo A; Bencheikh RS
    Ther Adv Drug Saf; 2012 Feb; 3(1):25-34. PubMed ID: 25083223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis.
    Olsson S; Pal SN; Stergachis A; Couper M
    Drug Saf; 2010 Aug; 33(8):689-703. PubMed ID: 20635827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.